For: | Freeman HJ. Colitis associated with biological agents. World J Gastroenterol 2012; 18(16): 1871-1874 [PMID: 22563166 DOI: 10.3748/wjg.v18.i16.1871] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v18/i16/1871.htm |
Number | Citing Articles |
1 |
Michael Au, Nikola Mitrev, Rupert W Leong, Viraj Kariyawasam. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World Journal of Clinical Cases 2022; 10(8): 2569-2576 doi: 10.12998/wjcc.v10.i8.2569
|
2 |
Jagpal S. Klair, Mohit Girotra, Laura F. Hutchins, Kari D. Caradine, Farshad Aduli, Mauricio Garcia-Saenz-de-Sicilia. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Digestive Diseases and Sciences 2016; 61(7): 2132 doi: 10.1007/s10620-016-4042-4
|
3 |
George E Fragoulis, Christina Liava, Dimitrios Daoussis, Euangelos Akriviadis, Alexandros Garyfallos, Theodoros Dimitroulas. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World Journal of Gastroenterology 2019; 25(18): 2162-2176 doi: 10.3748/wjg.v25.i18.2162
|
4 |
Francisco Mesonero, Antonio López-Sanromán, Ainhoa Madariaga, Ainara Soria. Colitis secundaria a ipilimumab: un nuevo reto para el gastroenterólogo. Gastroenterología y Hepatología 2016; 39(3): 233 doi: 10.1016/j.gastrohep.2015.06.005
|
5 |
Jennifer Seminerio, Kevin McGrath, Christina A. Arnold, Lysandra Voltaggio, Aatur D. Singhi. Medication-associated lesions of the GI tract. Gastrointestinal Endoscopy 2014; 79(1): 140 doi: 10.1016/j.gie.2013.08.027
|
6 |
Tasha Hughes, Howard L. Kaufman. Cancer Therapeutic Targets. 2013; : 1 doi: 10.1007/978-1-4614-6613-0_59-4
|
7 |
Dharma Budi Sunjaya, Cesar Taborda, Rebecca Obeng, Tanvi Dhere. First Case of Refractory Colitis Caused by Ocrelizumab. Inflammatory Bowel Diseases 2020; 26(6): e49 doi: 10.1093/ibd/izaa057
|
8 |
Ahmad Tarhini. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. Scientifica 2013; 2013: 1 doi: 10.1155/2013/857519
|
9 |
Hugh James Freeman. Spontaneous free perforation of the small intestine in adults. World Journal of Gastroenterology 2014; 20(29): 9990-9997 doi: 10.3748/wjg.v20.i29.9990
|
10 |
Cristina Saavedra, Francisco Mesonero, Cristian Perna, Pablo Reguera, Elena Corral, Reyes Ferreiro, Alfredo Carrato, Vanessa Pachón. Onset of ulcerative colitis and complete response during the treatment of a metastatic colon cancer: case report and literature review. Anti-Cancer Drugs 2021; 32(7): 763 doi: 10.1097/CAD.0000000000000922
|
11 |
Giovanni De Petris, Sonia Gatius Caldero, Longwen Chen, Shu-Yuan Xiao, Bal M. Dhungel, Amy J. Wendel Spizcka, Dora Lam-Himlin. Histopathological Changes in the Gastrointestinal Tract Due to Drugs. International Journal of Surgical Pathology 2014; 22(2): 120 doi: 10.1177/1066896913502229
|
12 |
Hsing Hwa Lee, Naveen Sritharan, Daniel Bermingham, Gabriela Strey, Matteo Neri. Ocrelizumab-Induced Severe Colitis. Case Reports in Gastrointestinal Medicine 2020; 2020: 1 doi: 10.1155/2020/8858378
|
13 |
Michael Vieth, Elizabeth Montgomery. Medication-associated gastrointestinal tract injury. Virchows Archiv 2017; 470(3): 245 doi: 10.1007/s00428-017-2077-3
|
14 |
Cailan Li, Guosong Wu, Hualang Zhao, Na Dong, Bowen Wu, Yujia Chen, Qiang Lu. Natural-Derived Polysaccharides From Plants, Mushrooms, and Seaweeds for the Treatment of Inflammatory Bowel Disease. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.651813
|
15 |
Giovanni Rossi, Aldo Pezzuto, Claudio Sini, Alessandro Tuzi, Fabrizio Citarella, Michael G. McCusker, Olga Nigro, Enrica Tanda, Alessandro Russo. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Critical Reviews in Oncology/Hematology 2019; 142: 26 doi: 10.1016/j.critrevonc.2019.07.005
|
16 |
Nissy A. Philip, Nazir Ahmed, Capecomorin S. Pitchumoni. Spectrum of Drug-induced Chronic Diarrhea. Journal of Clinical Gastroenterology 2017; 51(2): 111 doi: 10.1097/MCG.0000000000000752
|
17 |
Louis Libbrecht, Anne Jouret-Mourin, Karel Geboes. Colitis. 2018; : 169 doi: 10.1007/978-3-319-89503-1_11
|
18 |
A. Gupta, K. M. De Felice, E. V. Loftus, S. Khanna. Systematic review: colitis associated with anti‐CTLA‐4 therapy. Alimentary Pharmacology & Therapeutics 2015; 42(4): 406 doi: 10.1111/apt.13281
|
19 |
James E. Stefano, Julie Bird, Josephine Kyazike, Anthony Wai-Ming Cheng, Ekaterina Boudanova, Markryan Dwyer, Lihui Hou, Huawei Qiu, Gloria Matthews, Michael O’Callaghan, Clark Q. Pan. High-Affinity VEGF Antagonists by Oligomerization of a Minimal Sequence VEGF-Binding Domain. Bioconjugate Chemistry 2012; 23(12): 2354 doi: 10.1021/bc300301m
|
20 |
Martha R. Neagu, Russell W. Jenkins, David Reardon. Cancer Neurology in Clinical Practice. 2018; : 335 doi: 10.1007/978-3-319-57901-6_17
|
21 |
Hasan Yuksel, Ozge Yilmaz, Meral Karaman, H. Alper Bagriyanik, Fatih Firinci, Muge Kiray, Ahmet Turkeli, Ozkan Karaman. Role of vascular endothelial growth factor antagonism on airway remodeling in asthma. Annals of Allergy, Asthma & Immunology 2013; 110(3): 150 doi: 10.1016/j.anai.2012.12.015
|
22 |
Lei Zhao, John Hart. Histologic mimics of inflammatory bowel disease. Seminars in Diagnostic Pathology 2014; 31(2): 137 doi: 10.1053/j.semdp.2014.02.003
|
23 |
Niharika Mallepally, Hamzah Abu-Sbeih, Osman Ahmed, Ellie Chen, Mehnaz A. Shafi, Sattva S. Neelapu, Yinghong Wang. Clinical Features of Rituximab-associated Gastrointestinal Toxicities. American Journal of Clinical Oncology 2019; 42(6): 539 doi: 10.1097/COC.0000000000000553
|
24 |
Pablo Martinez Perez, Luke Hanna, Eleanor Jaynes, Markus Gwiggner. Infliximab rescue therapy in a case of severe granulomatous colitis associated with rituximab use. BMJ Case Reports 2024; 17(2): e257729 doi: 10.1136/bcr-2023-257729
|
25 |
Annarosa Floreani, Ying Sun, Zheng Sheng Zou, Baosen Li, Nora Cazzagon, Christopher L. Bowlus, M. Eric Gershwin. Proposed therapies in primary biliary cholangitis. Expert Review of Gastroenterology & Hepatology 2016; 10(3): 371 doi: 10.1586/17474124.2016.1121810
|
26 |
K. Khirfan, M. Kistin. Colitis Associated with Biological Agents. Digestive Diseases and Sciences 2014; 59(6): 1112 doi: 10.1007/s10620-014-3147-x
|
27 |
Uri Kopylov, Michael Starr, Craig Watts, Serge Dionne, Marc Girardin, Ernest G. Seidman. Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study. The Journal of Rheumatology 2018; 45(4): 498 doi: 10.3899/jrheum.161216
|
28 |
Kyung Won Kim, Nikhil H. Ramaiya, Katherine M. Krajewski, Atul B. Shinagare, Stephanie A. Howard, Jyothi P. Jagannathan, Nageatte Ibrahim. Ipilimumab-Associated Colitis: CT Findings. American Journal of Roentgenology 2013; 200(5): W468 doi: 10.2214/AJR.12.9751
|
29 |
Tobias Brummer, Tobias Ruck, Sven G. Meuth, Frauke Zipp, Stefan Bittner. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Therapeutic Advances in Neurological Disorders 2021; 14 doi: 10.1177/17562864211035542
|
30 |
Bindu Challa, Ashwini Kumar Esnakula. Histologic manifestations of ocrelizumab‐associated intestinal and hepatic injury in patients with multiple sclerosis. Histopathology 2024; 84(5): 765 doi: 10.1111/his.15120
|
31 |
Janaki Shah, Ahmad Al-Taaee, Parakkal Deepak, Anas Gremida. Severe Ocrelizumab-Induced Enterocolitis Treated Successfully With Ustekinumab. ACG Case Reports Journal 2022; 9(1): e00742 doi: 10.14309/crj.0000000000000742
|
32 |
Tasha Hughes, Howard L. Kaufman. Cancer Therapeutic Targets. 2017; : 157 doi: 10.1007/978-1-4419-0717-2_59
|
33 |
Poornima Varma, Julianne Falconer, Ahmad Aga, H. Miles Prince, Stephen Pianko. Rituximab-induced Crohn’s disease. Scandinavian Journal of Gastroenterology 2017; 52(5): 606 doi: 10.1080/00365521.2017.1280530
|
34 |
T. Steinmetz, A. Grossman, Y.A. Leshem, A. Gafter-Gvili. A case of pellagra associated with the use of bevacizumab. European Geriatric Medicine 2013; 4(6): 412 doi: 10.1016/j.eurger.2013.08.002
|
35 |
Midori Tanaka, Hidenobu Ishii, Koichi Azuma, Chika Saisho, Norikazu Matsuo, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Kazuhiko Yamada, Hidetoshi Takedatsu, Keiichi Mitsuyama, Tomoaki Hoshino. Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab. Investigational New Drugs 2015; 33(5): 1133 doi: 10.1007/s10637-015-0279-6
|
36 |
A. Aussy, N. Girszyn, T. Vandhuick, I. Marie, O. Vittecoq, H. Lévesque, Y. Benhamou. Rhumatisme psoriasique au cours d’un traitement par rituximab pour une polyangéïte avec granulomatose : une nouvelle réaction paradoxale ?. La Revue de Médecine Interne 2015; 36(7): 491 doi: 10.1016/j.revmed.2014.09.001
|
37 |
Jon Bjoern, Trine Zeeberg Iversen, Nikolaj Juul Nitschke, Mads Hald Andersen, Inge Marie Svane. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 2016; 18(8): 1043 doi: 10.1016/j.jcyt.2016.05.010
|
38 |
Ashwin N. Ananthakrishnan, Ramnik J. Xavier, Daniel K. Podolsky. Yamada' s Textbook of Gastroenterology. 2015; : 1364 doi: 10.1002/9781118512074.ch70
|
39 |
Francisco Mesonero, Antonio López-Sanromán, Ainhoa Madariaga, Ainara Soria. Ipilimumab-induced colitis: A new challenge for gastroenterologists. Gastroenterología y Hepatología (English Edition) 2016; 39(3): 233 doi: 10.1016/j.gastre.2016.02.016
|
40 |
Eesha Ashok, Nishith M Ekka, Dipendra K Sinha, Kumar Gaurav, Binay Kumar, Neyaz Ahmad, Deepak Kumar, Sumit Chandra, Prem P Choudhary. Clinical Presentations, Treatments, and Complications of Ileal Perforation at a Tertiary Center: A Cross-Sectional Study. Cureus 2024; doi: 10.7759/cureus.72027
|
41 |
Jessica K. Dyson, Gideon M. Hirschfield, David H. Adams, Ulrich Beuers, Derek A. Mann, Keith D. Lindor, David E. J. Jones. Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology & Hepatology 2015; 12(3): 147 doi: 10.1038/nrgastro.2015.12
|
42 |
Valdimar B. Kristjánsson, Sigrún H. Lund, Gerður Gröndal, Signý V. Sveinsdóttir, Hjálmar R. Agnarsson, Jón G. Jónasson, Einar S. Björnsson. Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scandinavian Journal of Gastroenterology 2021; 56(1): 46 doi: 10.1080/00365521.2020.1854847
|
43 |
Reem Akel, Bilal Anouti, Arafat Tfayli. Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report. Case Reports in Oncology 2017; 10(2): 456 doi: 10.1159/000475709
|
44 |
Vishal S. Chandan, Tsung-Teh Wu. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases. 2019; : 289 doi: 10.1007/978-3-030-15573-5_12
|
45 |
Andrew R. Barina, Mustafa R. Bashir, Brandon A. Howard, Brent A. Hanks, April K. Salama, Tracy A. Jaffe. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdominal Radiology 2016; 41(2): 207 doi: 10.1007/s00261-015-0560-3
|
46 |
Yue Xue, Alton Brad Farris, Brian Quigley, Alyssa Krasinskas. The Impact of New Technologic and Molecular Advances in the Daily Practice of Gastrointestinal and Hepatobiliary Pathology. Archives of Pathology & Laboratory Medicine 2017; 141(4): 517 doi: 10.5858/arpa.2016-0261-SA
|
47 |
Naoimh Herlihy, Roger Feakins. Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?. United European Gastroenterology Journal 2022; 10(5): 451 doi: 10.1002/ueg2.12242
|
48 |
S. Eldridge, M. Davis. Comprehensive Toxicology. 2018; : 219 doi: 10.1016/B978-0-12-801238-3.64269-1
|
49 |
Masahiro Nomura, Ryusuke Sumiya, Hayato Ono, Takeshi Nagai, Keigo Kumazawa, Atsushi Shimizu, Daisuke Endo, Nobuyoshi Aoyanagi. Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report. World Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-020-02114-0
|
50 |
Chantal Moyano, Mounir Beldjerd, Virginie Pécourneau, Thierry Billey, Slim Lassoued. Infection of the sigmoid colon during TNFα antagonist therapy for chronic inflammatory joint disease. Joint Bone Spine 2014; 81(3): 254 doi: 10.1016/j.jbspin.2013.09.008
|
51 |
Ian Brown, Gregory C. Miller. Endoscopic Biopsy Interpretation. 2019; : 259 doi: 10.1007/978-3-319-79117-3_10
|
52 |
Rachele Del Sordo, Vassilios Lougaris, Gabrio Bassotti, Alessandro Armuzzi, Vincenzo Villanacci. Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects. Clinical Immunology 2022; 234: 108916 doi: 10.1016/j.clim.2021.108916
|
53 |
François Aubin, Franck Carbonnel, Daniel Wendling. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013; 7(4): 257 doi: 10.1016/j.crohns.2012.06.024
|
54 |
Chantal Moyano, Mounir Beldjerd, Virginie Pécourneau, Thierry Billey, Slim Lassoued. Sigmoïdites infectieuses sous anti-TNFα lors de traitements pour rhumatismes inflammatoires chroniques. Revue du Rhumatisme 2014; 81(3): 255 doi: 10.1016/j.rhum.2013.08.006
|
55 |
Pingxin Zhang, Ren Mao, Chuhan Zhang, Yun Qiu, Minhu Chen. Gastrointestinal injury induced by immunomodulators: A review article. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231158549
|